G-CSF — White Blood Cell Growth Factor Support

Granulocyte colony-stimulating factor is a glycoprotein growth factor that regulates haematopoiesis by stimulating the proliferation, survival, and differentiation of neutrophil progenitor cells within the bone marrow. Under normal physiological conditions, endogenous G-CSF is produced by endothelial cells, macrophages, and other immune cells in response to infection and inflammatory cytokines.

In oncology, recombinant forms of G-CSF—such as filgrastim, lenograstim, and their long-acting pegylated equivalent, pegfilgrastim—are administered therapeutically. These pharmaceutical agents bind to specific G-CSF receptors on haematopoietic precursor cells, accelerating neutrophil maturation and shortening marrow transit time. Consequently, newly matured neutrophils enter systemic circulation more rapidly, reducing the duration and depth of treatment-induced neutropenia and facilitating the safe delivery of dose-dense chemotherapy schedules.

Neutropenia is one of the most hazardous side effects of modern cancer therapy. When neutrophil counts plunge, even minor bacterial infections can escalate rapidly into life-threatening emergencies. By administering G-CSF preventively or reactively, oncologists reduce the incidence of febrile neutropenia, decrease hospital admission rates, and curb the need for intravenous antibiotics. Crucially, maintaining safe neutrophil counts ensures that chemotherapy cycles stay on schedule without requiring dose reductions or treatment delays, thereby preserving the intended therapeutic efficacy and disease control against the underlying tumour.

The necessity and efficacy of G-CSF are monitored using a standard complete blood count (CBC) with differential. Clinicians specifically examine the absolute neutrophil count (ANC), calculated by multiplying the total white blood cell count by the percentage of neutrophils and bands. An ANC below 1.0 x 10^9/L indicates neutropenia. Monitoring bone marrow function through routine serial blood tests guides the timing, duration, and dosing of G-CSF injections.

G-CSF is widely prescribed across diverse solid tumours and haematological malignancies that require intensive, myelosuppressive chemotherapy regimens. It is routinely used in patients being treated for breast cancer, small cell and non-small cell lung cancer, ovarian carcinoma, and germ cell tumours. It is equally vital in blood cancers such as diffuse large B-cell lymphoma, Hodgkin lymphoma, and acute leukaemias, as well as during stem cell mobilization protocols before autologous transplantation.

G-CSF is administered subcutaneously, either daily (e.g., filgrastim) or as a single pegylated dose (e.g., pegfilgrastim) roughly 24 to 72 hours following chemotherapy. Common side effects include transient bone ache, particularly in the pelvis, sternum, or lower back, caused by bone marrow expansion. G-CSF is also used in stem cell mobilization protocols, guiding healthy peripheral blood stem cells into the bloodstream prior to autologous stem cell transplantation.